Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.61 |
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717995 | 0.81 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL719232 | 0.80 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL716444 | 0.80 | CASP3 (0.54) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL717576 | 0.79 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL716541 | 0.79 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL717074 | 0.78 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL716722 | 0.77 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL716771 | 0.77 | CASP3 (0.51) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL719495 | 0.74 | NPC1 (0.50) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL717615 | 0.73 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RAB9A 2454/4885NPC1 902/4885SMN1; SMN2 1051/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RAB9A 2454/4885NPC1 902/4885SMN1; SMN2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.